{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:36:41Z","timestamp":1791549401257,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1097\/igc.0b013e3182049273","type":"journal-article","created":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T00:36:16Z","timestamp":1292978176000},"page":"58-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Outcomes After Multiple Lines of Chemotherapy for Platinum-Resistant Epithelial Cancers of the Ovary, Peritoneum, and Fallopian Tube"],"prefix":"10.1016","volume":"21","author":[{"given":"Richard Wyn","family":"Griffiths","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Kiat","family":"Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saran","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gireesh C.","family":"Kumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon C.","family":"Jayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Clamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurjees","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e3182049273_bb0005","first-page":"71","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin."},{"key":"10.1097\/IGC.0b013e3182049273_bb0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1006\/gyno.1998.5237","article-title":"Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer","volume":"72","author":"Bolis","year":"1999","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0020","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0030","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0035","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0090-8258(03)00011-8","article-title":"Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer","volume":"88","author":"D\u2019Agostino","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0040","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0045","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PPO.0b013e3181b9c602","article-title":"Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials","volume":"15","author":"Buyse","year":"2009","journal-title":"Cancer Journal."},{"key":"10.1097\/IGC.0b013e3182049273_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00001703-199901000-00003","article-title":"The treatment of recurrent ovarian carcinoma: balancing patient desires, therapeutic benefit, cost containment and quality of life","volume":"11","author":"Bomalaski","year":"1999","journal-title":"Curr Opin Obstet Gynecol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0055","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1006\/gyno.2002.6748","article-title":"Treatment preferences in recurrent ovarian cancer","volume":"86","author":"Donovan","year":"2002","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0060","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ygyno.2005.03.022","article-title":"Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer","volume":"97","author":"Hoskins","year":"2005","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/annonc\/mdj032","article-title":"Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I\/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)","volume":"17","author":"du Bois","year":"2006","journal-title":"Ann Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjc.6600002","article-title":"Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer","volume":"86","author":"van der Burg","year":"2002","journal-title":"Br J Cancer."},{"key":"10.1097\/IGC.0b013e3182049273_bb0075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2003.09.021","article-title":"Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study","volume":"92","author":"Papadimitriou","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0080","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0085","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/gyno.2001.6489","article-title":"Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research","volume":"84","author":"Perez-Gracia","year":"2002","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182049273_bb0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"10.1097\/IGC.0b013e3182049273_bb0095","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"10.1097\/IGC.0b013e3182049273_bb0100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","volume":"360","year":"2002","journal-title":"Lancet."},{"key":"10.1097\/IGC.0b013e3182049273_bb0105","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1200\/JCO.2004.10.028","article-title":"Should CA-125 response criteria be preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?","volume":"22","author":"Gronlund","year":"2004","journal-title":"J Clin Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24200037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24200037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0b013e3182049273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:28:46Z","timestamp":1753223326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24200037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1048891X24200037"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e3182049273","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes After Multiple Lines of Chemotherapy for Platinum-Resistant Epithelial Cancers of the Ovary, Peritoneum, and Fallopian Tube","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e3182049273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2011 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}